{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 41,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "thesis_headline",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/35",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.115,
        "w": 0.916,
        "x": 0.056,
        "y": 0.175
      },
      "kind": "list",
      "text": "EXPERIENCED TEAM WITH TRACK RECORD OF SERIAL SUCCESSES: Seasoned drug developers who have advanced multiple programs from discovery to IND to global approvals",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c541938-4062-407f-9597-d013b1cf9cf5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.916,
        "x": 0.056,
        "y": 0.465
      },
      "kind": "list",
      "text": "BROAD PORTFOLIO TO ERASE CANCER: We have built one of the deepest pipelines in the industry to comprehensively shut down the RAS/MAPK pathway, with the potential to address unmet needs in over 5 million patients globally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "586bdfa4-546a-4e0d-b762-9b4faec68aeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.916,
        "x": 0.056,
        "y": 0.61
      },
      "kind": "list",
      "text": "THREE CLINICAL-STAGE COMPOUNDS: Differentiated profiles including naporafenib, a Phase 3-ready pan-RAF inhibitor for NRASm melanoma and Q61X tissue agnostic solid tumors, ERAS-007 ERK inhibitor, and ERAS-801, a CNS-penetrant EGFR inhibitor for GBM",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58b6ad1a-a068-4194-8cb2-4cdf0a7daf4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.916,
        "x": 0.056,
        "y": 0.32
      },
      "kind": "list",
      "text": "WORLD-CLASS SCIENTIFIC ADVISORY BOARD: Includes leading pioneers in: KRAS (Shokat, UCSF), SHP2 (Blacklow, HMS), ERK (Corcoran, MGH), RAS/MAPK pathway (Rodriguez-Viciana, UCL; Cichowski, HMS), precision oncology (Demetri, DFCI), and biopharma (Varney, Genentech)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91239340-9669-4b8d-bb8e-69e3060ea006",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.916,
        "x": 0.056,
        "y": 0.755
      },
      "kind": "list",
      "text": "MULTIPLE POTENTIAL NEAR-TERM AND LONG-TERM VALUE DRIVERS: Focused clinical development plan with multiple clinical readouts in 2024 and beyond and a strong research engine to drive first-in-class or best-in-class compounds into the clinic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef446d65-76db-45fe-8aee-479f7d63551c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.382,
        "x": 0.028,
        "y": 0.045
      },
      "kind": "title",
      "text": "Compelling investment thesis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40250fab-7602-4877-a2cf-ef0a4d071988",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "7ae6e770-5269-453a-866e-b445b50f6487",
      "evidence": "The slide presents a compelling investment thesis with multiple potential value drivers.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 38,
      "from": 31,
      "beatId": "655f0f34-999c-4f6f-9941-38fe6e021aa5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "Estimating the market potential of Erasca's treatments",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}